HALO Annual Total Long Term Liabilities
$1.54 B
-$3.96 M-0.26%
31 December 2023
Summary:
As of January 22, 2025, HALO annual total long term liabilities is $1.54 billion, with the most recent change of -$3.96 million (-0.26%) on December 31, 2023. During the last 3 years, it has risen by +$1.53 billion (+20414.79%). HALO annual total long term liabilities is now -0.26% below its all-time high of $1.54 billion, reached on December 31, 2022.HALO Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Quarterly Long Term Liabilities
$1.56 B
+$9.84 M+0.64%
30 September 2024
Summary:
As of January 22, 2025, HALO quarterly total long term liabilities is $1.56 billion, with the most recent change of +$9.84 million (+0.64%) on September 30, 2024. Over the past year, it has increased by +$28.22 million (+1.85%). HALO quarterly long term liabilities is now -6.13% below its all-time high of $1.66 billion, reached on September 30, 2022.HALO Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Long Term Liabilities Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -0.3% | +1.9% |
3 y3 years | +10000.0% | +1.9% |
5 y5 years | +3559.4% | +1.9% |
HALO Long Term Liabilities High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -0.3% | +94.5% | -6.1% | +97.0% |
5 y | 5-year | -0.3% | >+9999.0% | -6.1% | >+9999.0% |
alltime | all time | -0.3% | -6.1% |
Halozyme Therapeutics Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $1.56 B(+0.6%) |
June 2024 | - | $1.55 B(+1.0%) |
Mar 2024 | - | $1.53 B(-0.3%) |
Dec 2023 | $1.54 B(-0.3%) | $1.54 B(+0.6%) |
Sept 2023 | - | $1.53 B(-1.0%) |
June 2023 | - | $1.54 B(+0.1%) |
Mar 2023 | - | $1.54 B(+0.0%) |
Dec 2022 | $1.54 B(+95.0%) | $1.54 B(-7.1%) |
Sept 2022 | - | $1.66 B(+28.7%) |
June 2022 | - | $1.29 B(+63.1%) |
Mar 2022 | - | $790.30 M(-0.0%) |
Dec 2021 | $790.33 M(>+9900.0%) | $790.33 M(-0.0%) |
Sept 2021 | - | $790.59 M(-0.2%) |
June 2021 | - | $791.86 M(+0.0%) |
Mar 2021 | - | $791.57 M(>+9900.0%) |
Dec 2020 | $7.49 M(-98.1%) | $7.49 M(-98.1%) |
Sept 2020 | - | $398.06 M(+0.7%) |
June 2020 | - | $395.35 M(+0.8%) |
Mar 2020 | - | $392.31 M(+1.0%) |
Dec 2019 | $388.47 M(+824.9%) | $388.47 M(+2190.2%) |
Sept 2019 | - | $16.96 M(-24.1%) |
June 2019 | - | $22.36 M(-26.4%) |
Mar 2019 | - | $30.40 M(-27.6%) |
Dec 2018 | $42.00 M(-76.7%) | $42.00 M(-36.0%) |
Sept 2018 | - | $65.65 M(-24.9%) |
June 2018 | - | $87.40 M(-21.4%) |
Mar 2018 | - | $111.18 M(-38.3%) |
Dec 2017 | $180.25 M(-24.7%) | $180.25 M(-1.3%) |
Sept 2017 | - | $182.71 M(-10.4%) |
June 2017 | - | $204.01 M(-8.7%) |
Mar 2017 | - | $223.56 M(-6.6%) |
Dec 2016 | $239.41 M(+213.6%) | $239.41 M(-1.0%) |
Sept 2016 | - | $241.83 M(-2.2%) |
June 2016 | - | $247.32 M(+14.8%) |
Mar 2016 | - | $215.40 M(+182.2%) |
Dec 2015 | $76.33 M(-23.9%) | $76.33 M(-7.0%) |
Sept 2015 | - | $82.08 M(-7.5%) |
June 2015 | - | $88.78 M(-6.9%) |
Mar 2015 | - | $95.37 M(-4.9%) |
Dec 2014 | $100.29 M | $100.29 M(+11.3%) |
Date | Annual | Quarterly |
---|---|---|
Sept 2014 | - | $90.09 M(-5.2%) |
June 2014 | - | $95.03 M(+0.5%) |
Mar 2014 | - | $94.58 M(-2.4%) |
Dec 2013 | $96.88 M(+44.8%) | $96.88 M(+30.9%) |
Sept 2013 | - | $74.01 M(+16.7%) |
June 2013 | - | $63.41 M(-3.1%) |
Mar 2013 | - | $65.43 M(-2.2%) |
Dec 2012 | $66.93 M(+78.2%) | $66.93 M(+87.2%) |
Sept 2012 | - | $35.75 M(-1.7%) |
June 2012 | - | $36.37 M(-1.7%) |
Mar 2012 | - | $36.98 M(-1.5%) |
Dec 2011 | $37.56 M(-32.5%) | $37.56 M(+0.4%) |
Sept 2011 | - | $37.40 M(-1.4%) |
June 2011 | - | $37.91 M(-30.8%) |
Mar 2011 | - | $54.81 M(-1.5%) |
Dec 2010 | $55.65 M(-0.4%) | $55.65 M(+3.8%) |
Sept 2010 | - | $53.61 M(-1.7%) |
June 2010 | - | $54.54 M(-0.1%) |
Mar 2010 | - | $54.59 M(-2.2%) |
Dec 2009 | $55.85 M(+18.9%) | $55.85 M(+4.0%) |
Sept 2009 | - | $53.70 M(-1.8%) |
June 2009 | - | $54.69 M(+5.8%) |
Mar 2009 | - | $51.67 M(+10.0%) |
Dec 2008 | $46.96 M(+27.5%) | $46.96 M(+21.0%) |
Sept 2008 | - | $38.80 M(-1.7%) |
June 2008 | - | $39.49 M(-1.3%) |
Mar 2008 | - | $40.00 M(+8.6%) |
Dec 2007 | $36.83 M(+96.3%) | $36.83 M(+0.0%) |
Sept 2007 | - | $36.82 M(+34.5%) |
June 2007 | - | $27.37 M(-1.6%) |
Mar 2007 | - | $27.81 M(+48.2%) |
Dec 2006 | $18.76 M(>+9900.0%) | $18.76 M(>+9900.0%) |
Mar 2004 | - | $0.00(0.0%) |
Sept 2003 | - | $0.00(0.0%) |
June 2003 | - | $0.00(0.0%) |
Mar 2003 | - | $0.00(0.0%) |
Sept 2002 | - | $0.00(0.0%) |
June 2002 | - | $0.00(0.0%) |
Mar 2002 | - | $0.00 |
Dec 2001 | $0.00 | - |
FAQ
- What is Halozyme Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual total long term liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?
What is Halozyme Therapeutics annual total long term liabilities?
The current annual total long term liabilities of HALO is $1.54 B
What is the all time high annual total long term liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total long term liabilities is $1.54 B
What is Halozyme Therapeutics annual total long term liabilities year-on-year change?
Over the past year, HALO annual total long term liabilities has changed by -$3.96 M (-0.26%)
What is Halozyme Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of HALO is $1.56 B
What is the all time high quarterly long term liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total long term liabilities is $1.66 B
What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, HALO quarterly total long term liabilities has changed by +$28.22 M (+1.85%)